XERS Strangle Strategy
XERS (Xeris Biopharma Holdings, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
XERS (Xeris Biopharma Holdings, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.11B, a trailing P/E of 91.31, a beta of 0.92 versus the broader market, a 52-week range of 4.3-10.08, average daily share volume of 1.9M, a public-listing history dating back to 2018, approximately 394 full-time employees. These structural characteristics shape how XERS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.92 places XERS roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline. The trailing P/E of 91.31 is on the rich side, which tends to correlate with higher earnings-window IV expansion as the market debates whether forward growth supports the multiple.
What is a strangle on XERS?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current XERS snapshot
As of May 15, 2026, spot at $6.29, ATM IV 64.90%, IV rank 24.44%, expected move 18.61%. The strangle on XERS below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on XERS specifically: XERS IV at 64.90% is on the cheap side of its 1-year range, which favors premium-buying structures like a XERS strangle, with a market-implied 1-standard-deviation move of approximately 18.61% (roughly $1.17 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated XERS expiries trade a higher absolute premium for lower per-day decay. Position sizing on XERS should anchor to the underlying notional of $6.29 per share and to the trader's directional view on XERS stock.
XERS strangle setup
The XERS strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With XERS near $6.29, the first option leg uses a $6.60 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed XERS chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 XERS shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $6.60 | N/A |
| Buy 1 | Put | $5.98 | N/A |
XERS strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
XERS strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on XERS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on XERS
Strangles on XERS are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the XERS chain.
XERS thesis for this strangle
The market-implied 1-standard-deviation range for XERS extends from approximately $5.12 on the downside to $7.46 on the upside. A XERS long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current XERS IV rank near 24.44% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on XERS at 64.90%. As a Healthcare name, XERS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to XERS-specific events.
XERS strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. XERS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move XERS alongside the broader basket even when XERS-specific fundamentals are unchanged. Always rebuild the position from current XERS chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on XERS?
- A strangle on XERS is the strangle strategy applied to XERS (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With XERS stock trading near $6.29, the strikes shown on this page are snapped to the nearest listed XERS chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are XERS strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the XERS strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 64.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a XERS strangle?
- The breakeven for the XERS strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current XERS market-implied 1-standard-deviation expected move is approximately 18.61%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on XERS?
- Strangles on XERS are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the XERS chain.
- How does current XERS implied volatility affect this strangle?
- XERS ATM IV is at 64.90% with IV rank near 24.44%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.